Market Research Logo

Kidney Transplantation - Pipeline Review, H2 2015

Kidney Transplantation - Pipeline Review, H2 2015

Summary

Global Markets Direct’s, ‘Kidney transplantation - Pipeline Review, H2 2015’, provides an overview of the Kidney transplantation’s therapeutic pipeline.

This report provides comprehensive information on the therapeutic development for Kidney transplantation, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Kidney transplantation and special features on late-stage and discontinued projects.

Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct’s team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

  • The report provides a snapshot of the global therapeutic landscape of Kidney transplantation
  • The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities
  • The report reviews key players involved in the therapeutics development for Kidney transplantation and enlists all their major and minor projects
  • The report summarizes all the dormant and discontinued pipeline projects
  • A review of the Kidney transplantation products under development by companies and universities/research institutes based on information derived from company and industry-specific sources
  • Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages
  • A detailed assessment of monotherapy and combination therapy pipeline projects
  • Coverage of the Kidney transplantation pipeline on the basis of target, MoA, route of administration and molecule type
  • Latest news and deals relating related to pipeline products
Reasons to buy
  • Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies
  • Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
  • Develop strategic initiatives by understanding the focus areas of leading companies
  • Identify and understand important and diverse types of therapeutics under development for Kidney transplantation
  • Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline
  • Devise corrective measures for pipeline projects by understanding Kidney transplantation pipeline depth and focus of Indication therapeutics
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
  • Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline


Introduction
Global Markets Direct Report Coverage
Kidney Transplantation Overview
Therapeutics Development
Pipeline Products for Kidney Transplantation - Overview
Pipeline Products for Kidney Transplantation - Comparative Analysis
Kidney Transplantation - Therapeutics under Development by Companies
Kidney Transplantation - Therapeutics under Investigation by Universities/Institutes
Kidney Transplantation - Pipeline Products Glance
Late Stage Products
Clinical Stage Products
Early Stage Products
Unknown Stage Products
Kidney Transplantation - Products under Development by Companies
Kidney Transplantation - Products under Investigation by Universities/Institutes
Kidney Transplantation - Companies Involved in Therapeutics Development
Alexion Pharmaceuticals, Inc.
Amyndas Pharmaceuticals LLC
Angion Biomedica Corp.
Astellas Pharma Inc.
Bio-inRen
Catalyst Biosciences, Inc.
CSL Limited
Digna Biotech, S.L.
Dompe Farmaceutici S.p.A.
Effimune SAS
GlaxoSmithKline Plc
Grifols, S.A.
Hansa Medical AB
Kyowa Hakko Kirin Co., Ltd.
Mabtech Limited
Novartis AG
Onyx Pharmaceuticals, Inc.
Opsona Therapeutics Limited
Pharming Group N.V.
Prolong Pharmaceuticals
Quark Pharmaceuticals, Inc.
Shire Plc
t-cell Europe GmbH
Tiziana Life Sciences Plc
Zyrnat Biotherapeutics SL
Kidney Transplantation - Therapeutics Assessment
Assessment by Monotherapy Products
Assessment by Target
Assessment by Mechanism of Action
Assessment by Route of Administration
Assessment by Molecule Type
Drug Profiles
albumin (human) - Drug Profile
Product Description
Mechanism of Action
R&D Progress
AMY-101 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
AS-2521780 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
basiliximab biobetter - Drug Profile
Product Description
Mechanism of Action
R&D Progress
BB-3 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
belimumab - Drug Profile
Product Description
Mechanism of Action
R&D Progress
bleselumab - Drug Profile
Product Description
Mechanism of Action
R&D Progress
BRN-1889 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
C1 esterase inhibitor (human) - Drug Profile
Product Description
Mechanism of Action
R&D Progress
C1 esterase inhibitor (human) - Drug Profile
Product Description
Mechanism of Action
R&D Progress
C1 esterase inhibitor (human) - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Cardiotrophin-1 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
carfilzomib - Drug Profile
Product Description
Mechanism of Action
R&D Progress
CB-2782 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Cell Therapy for Kidney Transplantation - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Cell Therapy for Kidney Transplantation - Drug Profile
Product Description
Mechanism of Action
R&D Progress
CFZ-533 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Dendritic Cell Therapy for Multiple Sclerosis and Kidney Transplantation - Drug Profile
Product Description
Mechanism of Action
R&D Progress
eculizumab - Drug Profile
Product Description
Mechanism of Action
R&D Progress
EFFI-7H - Drug Profile
Product Description
Mechanism of Action
R&D Progress
ETR-002 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
FCR-001 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
foralumab - Drug Profile
Product Description
Mechanism of Action
R&D Progress
FR-104 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
FX-06 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Monoclonal Antibody to Inhibit CD47 for Kidney Transplantation, Cardiovascular Disease and Oncology - Drug Profile
Product Description
Mechanism of Action
R&D Progress
OPN-305 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
QPI-1002 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Recombinant Enzyme to Inhibit Immunoglobulin G for Kidney Transplantation - Drug Profile
Product Description
Mechanism of Action
R&D Progress
reparixin - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Sanguinate - Drug Profile
Product Description
Mechanism of Action
R&D Progress
T-Cell Therapy for Kidney Transplant - Drug Profile
Product Description
Mechanism of Action
R&D Progress
ZY-11 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Kidney Transplantation - Recent Pipeline Updates
Kidney Transplantation - Dormant Projects
Kidney Transplantation - Dormant Projects
Kidney Transplantation - Discontinued Products
Kidney Transplantation - Product Development Milestones
Featured News & Press Releases
Oct 13, 2015: Shire's CINRYZE (C1 esterase inhibitor [human]) Receives FDA Fast Track Designation for Investigation in the Treatment of Antibody Mediated Rejection in Patients Receiving Kidney Transplants
Sep 15, 2015: Data from Hansa Medical’s First Phase II study of IdeS in Sensitized Kidney Transplantation Patients Presented in Oral Session at ESOT 2015
Sep 14, 2015: Hansa Medical receives FDA Orphan Drug Designation for IdeS
Aug 11, 2015: First patient in IdeS study at Cedars-Sinai Medical Center in Los Angeles receives kidney transplantation
Jul 22, 2015: TRACT Therapeutics Completes Phase I Safety Trial Using a Patient’s Immune Cells to Prevent Organ Rejection
Jul 09, 2015: Effimune launches Phase I clinical trial on immune system regulation control
May 14, 2015: Angion Biomedica Advances BB3 into Pivotal Phase 3 Clinical Trial in Renal Transplant Patients with Delayed Graft Function
May 06, 2015: Hansa Medical Establishes a US medical advisory board for IdeS in kidney transplantation
Apr 13, 2015: Alexion Announces Presentations at 2015 American Transplant Congress, Including Results from Studies Advancing the Understanding of Eculizumab (Soliris) in Patients Undergoing Kidney Transplant
Feb 12, 2015: Hansa Medical develops second-generation IdeS molecules for repeat dosing
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer
List of Tables
Number of Products under Development for Kidney Transplantation, H2 2015
Number of Products under Development for Kidney Transplantation - Comparative Analysis, H2 2015
Number of Products under Development by Companies, H2 2015
Number of Products under Investigation by Universities/Institutes, H2 2015
Comparative Analysis by Late Stage Development, H2 2015
Comparative Analysis by Clinical Stage Development, H2 2015
Comparative Analysis by Early Stage Development, H2 2015
Comparative Analysis by Unknown Stage Development, H2 2015
Products under Development by Companies, H2 2015
Products under Development by Companies, H2 2015 (Contd..1)
Products under Investigation by Universities/Institutes, H2 2015
Kidney Transplantation - Pipeline by Alexion Pharmaceuticals, Inc., H2 2015
Kidney Transplantation - Pipeline by Amyndas Pharmaceuticals LLC, H2 2015
Kidney Transplantation - Pipeline by Angion Biomedica Corp., H2 2015
Kidney Transplantation - Pipeline by Astellas Pharma Inc., H2 2015
Kidney Transplantation - Pipeline by Bio-inRen, H2 2015
Kidney Transplantation - Pipeline by Catalyst Biosciences, Inc., H2 2015
Kidney Transplantation - Pipeline by CSL Limited, H2 2015
Kidney Transplantation - Pipeline by Digna Biotech, S.L., H2 2015
Kidney Transplantation - Pipeline by Dompe Farmaceutici S.p.A., H2 2015
Kidney Transplantation - Pipeline by Effimune SAS, H2 2015
Kidney Transplantation - Pipeline by GlaxoSmithKline Plc, H2 2015
Kidney Transplantation - Pipeline by Grifols, S.A., H2 2015
Kidney Transplantation - Pipeline by Hansa Medical AB, H2 2015
Kidney Transplantation - Pipeline by Kyowa Hakko Kirin Co., Ltd., H2 2015
Kidney Transplantation - Pipeline by Mabtech Limited, H2 2015
Kidney Transplantation - Pipeline by Novartis AG, H2 2015
Kidney Transplantation - Pipeline by Onyx Pharmaceuticals, Inc., H2 2015
Kidney Transplantation - Pipeline by Opsona Therapeutics Limited, H2 2015
Kidney Transplantation - Pipeline by Pharming Group N.V., H2 2015
Kidney Transplantation - Pipeline by Prolong Pharmaceuticals, H2 2015
Kidney Transplantation - Pipeline by Quark Pharmaceuticals, Inc., H2 2015
Kidney Transplantation - Pipeline by Shire Plc, H2 2015
Kidney Transplantation - Pipeline by t-cell Europe GmbH, H2 2015
Kidney Transplantation - Pipeline by Tiziana Life Sciences Plc, H2 2015
Kidney Transplantation - Pipeline by Zyrnat Biotherapeutics SL, H2 2015
Assessment by Monotherapy Products, H2 2015
Number of Products by Stage and Target, H2 2015
Number of Products by Stage and Mechanism of Action, H2 2015
Number of Products by Stage and Route of Administration, H2 2015
Number of Products by Stage and Molecule Type, H2 2015
Kidney Transplantation Therapeutics - Recent Pipeline Updates, H2 2015
Kidney Transplantation - Dormant Projects, H2 2015
Kidney Transplantation - Discontinued Products, H2 2015
List of Figures
Number of Products under Development for Kidney Transplantation, H2 2015
Number of Products under Development for Kidney Transplantation - Comparative Analysis, H2 2015
Number of Products under Development by Companies, H2 2015
Comparative Analysis by Clinical Stage Development, H2 2015
Comparative Analysis by Early Stage Products, H2 2015
Assessment by Monotherapy Products, H2 2015
Number of Products by Top 10 Targets, H2 2015
Number of Products by Stage and Top 10 Targets, H2 2015
Number of Products by Top 10 Mechanism of Actions, H2 2015
Number of Products by Stage and Top 10 Mechanism of Actions, H2 2015
Number of Products by Routes of Administration, H2 2015
Number of Products by Stage and Routes of Administration, H2 2015
Number of Products by Molecule Types, H2 2015
Number of Products by Stage and Molecule Types, H2 2015

Download our eBook: How to Succeed Using Market Research

Learn how to effectively navigate the market research process to help guide your organization on the journey to success.

Download eBook

Share this report